Skip to main content
  • Home
  • Library
  • Read
    • Popular
    • Charts
    • Browse
    • Categories
    • Wikis
    • Glossary
  • Request
  • Activity
  • Leaderboard
  • Help
Our Apps
  • DaoSearch
  • Narratorr
Social
  • Discord
  • Patreon
I Can Extract Side Effects
Chapter 212

212. Seven New Drugs

1,463 words 5 min read 1 view 4mo ago Source ​
Skip to the end of the chapter
Prev
Next

These seven prescriptions were carefully selected from more than one hundred prescriptions in the important categories.

Of the remaining prescriptions, there were naturally some with very good side effects, but none of them appealed to him as much as these seven.

We can only select the best of the best and develop these seven drugs first.

As for the others, we can choose them when we need new drugs.

It's important to understand that every drug requires massive resources from research and development to market launch, including R&D investment, clinical trials, production and sales, and a whole host of other expenses.

Of these costs, clinical trials account for the largest share, roughly two-thirds of the total.

While the pure R&D investment is substantial, it is not the largest compared to subsequent development costs.

Many small pharmaceutical companies or laboratories are capable of developing a new drug on their own, but they often lack follow-up funding and are unable to continue clinical trials, making it impossible to market the drug. They have no choice but to sell the formula to large pharmaceutical companies to recover their costs as soon as possible.

Only large pharmaceutical companies have the resources to invest heavily in subsequent clinical trials before bringing the product to market.

Large pharmaceutical companies can only invest in clinical trials for a limited number of drugs each year. They cannot conduct clinical trials on all the drugs they are developing, and can only choose from a large number of new drugs.

Many promising drugs, even if they are developed, will only gather dust in cabinets if they are not further developed.

There are many similar examples in the history of drug development.

In the late 1950s, the first panacea for treating Depression Imipramine, was introduced. It was originally developed as a new drug for schizophrenia, but doctors found it ineffective during clinical trials.

Because the doctor was very interested in Depression, he directly used the new drug on patients with Depression. A few days later, the doctor was surprised to find that the patients had recovered.

In his excitement, the doctor contacted Novartis to inform them of the matter. However, Novartis did not respond at all and even prohibited the doctor from using the new drug to treat Depression, because they did not care about Depression at all and only wanted to develop a drug to treat schizophrenia.

Just as this miracle drug was about to be swept into the dustbin of history, the wife of a major Novartis shareholder suddenly developed Depression. He asked the doctor what medicine could treat it, and the doctor immediately recommended Imipramine.

The major shareholder's wife recovered quickly after using the new drug. Seeing the miraculous effect, he lobbied Novartis to launch the drug, which finally made this once-promising but now difficult-to-produce drug shine.

Historically, many new drugs, after being successfully developed, have failed completely at the clinical trial and marketing stage.

This shows that successful drug development is only the first step in a long journey. Only through a series of subsequent clinical trials and promotions can a drug be successfully launched on the market and exert its due therapeutic effect on patients.

No matter how many drugs Wei Kang extracts, if they cannot be put into clinical use and transformed into over-the-counter drugs as soon as possible, they are just a pile of idle prescriptions to him, and may even arouse suspicion from those with ulterior motives.

Therefore, extracting seven prescriptions at a time was enough for him.

The right approach is to take a steady, gradual approach, extracting profits slowly and releasing them one by one to the market, turning them into cash cows.

Next, we will invest personnel and resources to fully advance clinical trials and market launch.

However, before that, Wei Kang checked the inventor's information as usual.

As expected, the inventor of the Pet Medicine was Chen Yiqing. He finally achieved his wish and developed a highly effective drug to treat feline infectious Peritonitis, a terminal illness.

He originally intended to develop a specific drug for feline Kidney Failure, but despite his tireless efforts, he repeatedly failed, showing that he really didn't have much talent in veterinary medicine. However, by sheer luck, he was able to treat Feline Infectious Peritonitis, which can be considered as fate.

If a pet lover like him knew that his company was going to enter the Veterinary Medicine field and had even come up with a flagship drug, he would probably be extremely happy.

The inventor of the insecticide turned out to be Gu Xian. After joining the company for some time, he finally began to develop a new drug.

Perhaps to test the waters, they didn't start with highly challenging innovative drugs, but instead began by improving some existing drugs. Although the effects were minimal, they still produced an excellent product during the research and development process.

Wei Kang was deeply gratified and couldn't help but feel happy for Gu Xian.

The fact that he has been able to shift from generic drugs to innovative drugs shows that he is making continuous progress and striving to reach new heights in technology, which is truly commendable.

As for the inventors of the other five drugs, they were all unfamiliar new names. After checking the information, they were all new employees.

One of the girls, named Zhang Li, caught his attention.

Zhang Li originally wanted to develop a dopamine receptor antagonist, but it didn't work. For some reason, the discarded prescription developed a side effect of blocking allergic reactions, which could be considered a case of unintended consequences.

The more Wei Kang looked at these newcomers, the more satisfied he became.

Excellent, excellent. They are all promising newcomers. Not only are they hardworking, but they also actively respond to the company's call and strive to develop new drugs. They deserve to be nurtured.

This year's Million President's Award has been given to seven individuals, which is enough to prove that the company is truly a place where talents flourish and a gathering of outstanding individuals.

He frowned, suddenly remembering Xiang Gaofei, who had contributed several drugs last time. His name hadn't appeared, and he hadn't contributed any discarded prescriptions.

After thinking about it, he suddenly realized that this person had already been sent by him to manage the Dragon Map Branch Office.

The Sanqing Group has lost a lucky member! Wei Kang couldn't help but beat his chest and stamp his feet, a faint sense of loss rising in his heart.

However, there's nothing that can be done. Xiang Gaofei is now a powerful figure in his own right, with his performance steadily improving and his career flourishing. He probably doesn't have the mind to develop any new drugs.

Sigh, it seems we still need to keep cultivating new talent and strive to discover one, no, several new lucky winners as soon as possible.

Only in this way can the losses be minimized and the void left by Xiang Gaofei's departure from the R&D department be filled.

Finally, Wei Kang summoned the system, and without looking at anything else, began the extraction process.

"System, extract this side effect of inhibiting platelet aggregation and dissolving fibrin, and formulate a new drug."

"System, extract this side effect of regulating the body's ion balance and formulate a new drug."

"System, extract..."

They extracted it seven times in one go, without stopping.

Below the system panel, light continuously emanated, revealing one new prescription after another.

The system remains remarkable. By changing the proportions of the raw materials and adding some additional ingredients to the original prescription, a new small molecule drug was created, making it a completely new drug.

Wei Kang copied down the prescription in front of him and smiled with satisfaction.

The company is about to open up a new battlefield, venturing into the fields of pesticides and Veterinary Medicine.

These two markets are still very large, enough to deepen and widen the moat of Sanqing Group.

To be honest, he was quite envious of Bayer in this respect.

Bayer Crop Science, one of the three major subsidiaries of the Bayer Group, is mainly engaged in crop protection, non-agricultural pest control, seeds and biotechnology. Its cockroach medicine, Pet Medicine and pesticides are very famous and have a high market share.

If Three Purities can gradually enter these fields and become the top choice for domestic products, it will naturally be able to completely replace Bayer and seize this big market share.

Scar Removal Cream and hair removal cream will undoubtedly become popular worldwide, further boosting the popularity of Sanqing Beauty.

As for anti-allergy medications, they are widely used in prescription drugs, over-the-counter drugs, and even in the field of skincare and beauty.

Of course, the most important medications are Antihypertensive Drug and Anti-thrombotic Drug.

These two are truly the trump cards.

End of Chapter
Prev
NovelSummaries
Next

Explore the wiki

Wei Kang

Comments

No comments yet.
AboutStatsAPIChangelogStatusContactPrivacyTermsDMCA
© 2026 RandomTranslator·v3.26·RSS